279 related articles for article (PubMed ID: 23901018)
1. Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients.
Engstrøm MJ; Opdahl S; Hagen AI; Romundstad PR; Akslen LA; Haugen OA; Vatten LJ; Bofin AM
Breast Cancer Res Treat; 2013 Aug; 140(3):463-73. PubMed ID: 23901018
[TBL] [Abstract][Full Text] [Related]
2. Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study.
Zhou W; Jirström K; Amini RM; Fjällskog ML; Sollie T; Lindman H; Sørlie T; Blomqvist C; Wärnberg F
BMC Cancer; 2013 Oct; 13():512. PubMed ID: 24171825
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
4. Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study.
Su Y; Zheng Y; Zheng W; Gu K; Chen Z; Li G; Cai Q; Lu W; Shu XO
BMC Cancer; 2011 Jul; 11():292. PubMed ID: 21749714
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
[TBL] [Abstract][Full Text] [Related]
6. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
[TBL] [Abstract][Full Text] [Related]
7. Anthropometric factors and risk of molecular breast cancer subtypes among postmenopausal Norwegian women.
Horn J; Alsaker MD; Opdahl S; Engstrøm MJ; Tretli S; Haugen OA; Bofin AM; Vatten LJ; Asvold BO
Int J Cancer; 2014 Dec; 135(11):2678-86. PubMed ID: 24752603
[TBL] [Abstract][Full Text] [Related]
8. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study.
Dawood S; Hu R; Homes MD; Collins LC; Schnitt SJ; Connolly J; Colditz GA; Tamimi RM
Breast Cancer Res Treat; 2011 Feb; 126(1):185-92. PubMed ID: 20711652
[TBL] [Abstract][Full Text] [Related]
9. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
[TBL] [Abstract][Full Text] [Related]
11. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
Matsubara N; Mukai H; Fujii S; Wada N
Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
[TBL] [Abstract][Full Text] [Related]
12. Survival time and molecular subtypes of breast cancer after radiotherapy in Thailand.
Kongsiang A; Tangvoraphonkchai V; Jirapornkul C; Promthet S; Kamsa-Ard S; Suwanrungruang K
Asian Pac J Cancer Prev; 2014; 15(23):10505-8. PubMed ID: 25556500
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer in young women and prognosis: How important are proliferation markers?
Fredholm H; Magnusson K; Lindström LS; Tobin NP; Lindman H; Bergh J; Holmberg L; Pontén F; Frisell J; Fredriksson I
Eur J Cancer; 2017 Oct; 84():278-289. PubMed ID: 28844016
[TBL] [Abstract][Full Text] [Related]
14. Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy.
Liu FF; Shi W; Done SJ; Miller N; Pintilie M; Voduc D; Nielsen TO; Nofech-Mozes S; Chang MC; Whelan TJ; Weir LM; Olivotto IA; McCready DR; Fyles AW
J Clin Oncol; 2015 Jun; 33(18):2035-40. PubMed ID: 25964246
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
16. Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?
Albergaria A; Ricardo S; Milanezi F; Carneiro V; Amendoeira I; Vieira D; Cameselle-Teijeiro J; Schmitt F
BMC Cancer; 2011 Jul; 11():299. PubMed ID: 21762477
[TBL] [Abstract][Full Text] [Related]
17. Locoregional recurrence by molecular subtype after multicatheter interstitial accelerated partial breast irradiation: Results from the Pooled Registry Of Multicatheter Interstitial Sites research group.
Anderson BM; Kamrava M; Wang PC; Chen P; Demanes DJ; Hayes JK; Kuske RR
Brachytherapy; 2016; 15(6):788-795. PubMed ID: 27743957
[TBL] [Abstract][Full Text] [Related]
18. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies.
Blows FM; Driver KE; Schmidt MK; Broeks A; van Leeuwen FE; Wesseling J; Cheang MC; Gelmon K; Nielsen TO; Blomqvist C; Heikkilä P; Heikkinen T; Nevanlinna H; Akslen LA; Bégin LR; Foulkes WD; Couch FJ; Wang X; Cafourek V; Olson JE; Baglietto L; Giles GG; Severi G; McLean CA; Southey MC; Rakha E; Green AR; Ellis IO; Sherman ME; Lissowska J; Anderson WF; Cox A; Cross SS; Reed MW; Provenzano E; Dawson SJ; Dunning AM; Humphreys M; Easton DF; García-Closas M; Caldas C; Pharoah PD; Huntsman D
PLoS Med; 2010 May; 7(5):e1000279. PubMed ID: 20520800
[TBL] [Abstract][Full Text] [Related]
19. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
20. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
Falck AK; Bendahl PO; Chebil G; Olsson H; Fernö M; Rydén L
Breast Cancer Res Treat; 2013 Jul; 140(1):93-104. PubMed ID: 23807420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]